Effect of propofol on seizure-like phenomena and electroencephalographic activity in children with epilepsy vs

S Meyer1, M G Shamdeen, B Kegel

  • 1Department of Paediatrics and Paediatric Intensive Care Medicine, University Hospital of Saarland, Homburg, Germany.

Anaesthesia
|October 18, 2006
PubMed

Insights

Propofol sedation did not cause seizures in children with epilepsy or learning difficulties. The study suggests propofol has anticonvulsant properties, showing transient EEG changes like suppressed spike-wave patterns in epilepsy patients.

Area of Science:

  • Pediatric Neurology
  • Anesthesiology
  • Clinical Neurophysiology

Background:

  • The use of propofol in epileptic patients is debated due to potential pro- or anticonvulsant effects.
  • Understanding propofol's impact on electroencephalogram (EEG) activity is crucial for patient safety during sedation.

Purpose of the Study:

  • To prospectively assess seizure-like phenomena and EEG changes induced by propofol sedation in children with epilepsy and learning difficulties.
  • To evaluate propofol's potential anticonvulsant properties in pediatric patients.

Main Methods:

  • Prospective study involving 25 children with epilepsy and 25 with learning difficulties undergoing MRI sedation.
  • EEG monitoring was conducted during and after intravenous propofol administration.
  • Occurrence of seizure-like phenomena and specific EEG patterns (beta, theta, spike-wave) were analyzed.

Main Results:

  • No child exhibited seizure-like phenomena of epileptic origin during or after propofol sedation.
  • Propofol induced transient EEG changes, including increased beta activity and suppression of theta rhythms in both groups.
  • In children with epilepsy, propofol suppressed pre-existing spike-wave patterns, indicating anticonvulsant effects.

Conclusions:

  • Propofol sedation is safe regarding seizure induction in children with epilepsy and learning difficulties.
  • The observed EEG changes, particularly the suppression of spike-wave activity, support propofol's anticonvulsant properties.
  • Propofol can be considered a sedative-hypnotic agent with potential benefits in managing epilepsy-related EEG activity.

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Seizures l: Introduction01:20

Seizures l: Introduction

Understanding seizures and epilepsy relies on key definitions that help in recognizing, classifying, and managing these disorders. These definitions provide a framework for recognizing, classifying, and managing seizure disorders.DefinitionsA seizure is a sudden, abnormal burst of electrical activity in the brain that can cause changes in awareness, movement, sensation, or behavior, depending on the area involved. Epilepsy is a chronic condition characterized by recurrent, unprovoked seizures,...
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Epilepsy ll: Types01:22

Epilepsy ll: Types

Recurrent seizures, stemming from abnormal electrical activity in the brain, are the defining characteristic of epilepsy, a chronic neurological condition. Because seizure features vary greatly, epilepsy is classified using two systems: by seizure type and by epilepsy syndromes. These classifications enable clinicians to describe seizure patterns and select suitable treatment strategies.I. Classification by Seizure Type1. Focal EpilepsyFocal epilepsy begins in one hemisphere of the brain.